Scott T. Tagawa, MD, FACP, reviews the use of 177Lu-PSMA-617 radioligand therapy and clinical implications from the phases 3 VISION trial for patients with metastatic castration-resistant prostate cancer (mCRPC).
EP. 1: Overview of Prostate Cancer
Scott T. Tagawa, MD, FACP, discusses the heterogeneity and features of prostate cancer and provides insight on biomarker testing.
EP. 2: Role of Imaging in Prostate Cancer
Dr Scott T. Tagawa reviews traditional imaging techniques and advances in imaging used in clinical practice for prostate cancer.
EP. 3: Treatment Options for Metastatic CRPC
An expert in prostate cancer reviews available options for the treatment of mCRPC and considerations for selecting the optimal therapy.
EP. 4: Phase 3 VISION Trial in mCRPC
Scott T. Tagawa, MD, FACP, reviews the phase 3 VISION trial evaluating the use of 177Lu-PSMA-617 therapy in patients with mCRPC.
EP. 5: Clinical Implications From the VISION Trial in mCRPC
A prostate cancer expert considers clinical implications from the phase 3 VISION study, including the potential role of 177Lu-PSMA-617 therapy for patients with mCRPC.
EP. 6: LuPSMA Therapy in mCRPC: Managing Adverse Events
Dr Scott T. Tagawa discusses common adverse events associated with 177Lu-PSMA-617 in patients with mCRPC and how to appropriately manage them.
EP. 7: Remaining Questions for LuPSMA Therapy in mCRPC
Scott T. Tagawa, MD, FACP, shares his thoughts on remaining questions for imaging and PSMA-targeted therapy for mCRPC.
EP. 8: Future Treatment Landscape of mCRPC
An expert in prostate cancer comments on emerging agents and combinations in the pipeline for the treatment of mCRPC.
EP. 9: Clinical Pearls for the Management of mCRPC
Scott T. Tagawa, MD, FACP, shares clinical pearls and advice for the management of mCRPC.
2 Clarke Drive Cranbury, NJ 08512